The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Open accessAbstract
Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ∼30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Among patients for whom R-CHOP therapy fails, 20% suffer from primary refractory disease (progress during or right after treatment) whereas 30% relapse after achieving complete remission (CR). Currently, there is no good definition enabling us to identify these 2 groups upon diagnosis. Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture. New strategies are currently being explored to obtain better CR rates and fewer relapses. Although young relapsing patients are treated with high-dose therapy followed by autologous transplant, there is an unmet need for better salvage regimens in this setting. To prevent relapse, maintenance therapy with immunomodulatory agents such as lenalidomide is currently undergoing investigation. New drugs will most likely be introduced over the next few years and will probably be different for relapsing and refractory patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Horn, H., Ziepert, M., Becher, C., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-435842 · Cited by 542
Roschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70106-3 · Cited by 463
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Xu-Monette, Z. Y., Wu, L., Visco, C., Tai, Y. C., Tzankov, A., Liu, W.-M., Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433334 · Cited by 388
Viardot, A., Goebeler, M.-E., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Sayehli, C., Stieglmaier, J., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651380 · Cited by 378
Récher, C., Coiffier, B., Haioun, C., Molina, T. J., Fermé, C., Casasnovas, O., Thiéblemont, C., Bosly, A., Laurent, G., Morschhauser, F., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61040-4 · Cited by 355
Self-citationRossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Anderson, M. A., Deng, J., Seymour, J. F., Tam, C., Kim, S. Y., Fein, J., Yu, L., Brown, J. R., Westerman, D., Si, E. G., et al. (2016) · Blood · doi:10.1182/blood-2016-01-688796 · Cited by 316
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 300
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 281
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Copie-Bergman, C., Cuillière-Dartigues, P., Baia, M., Briere, J., Delarue, R., Canioni, D., Salles, G., Parrens, M., Belhadj, K., Fabiani, B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647602 · Cited by 255
Pregno, P., Chiappella, A., Bellò, M., Botto, B., Ferrero, S., Franceschetti, S., Giunta, F., Ladetto, M., Limerutti, G., Menga, M., et al. (2012) · Blood · doi:10.1182/blood-2011-06-359943 · Cited by 236
Sehn, L. H., Scott, D. W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., Connors, J. M., & Gascoyne, R. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3419 · Cited by 232
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Morin, R. D., Assouline, S., Alcaide, M., Mohajeri, A., Johnston, R. L., Chong, L., Grewal, J., Yu, S., Fornika, D., Bushell, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2123 · Cited by 221
Friedberg, J. W., Mahadevan, D., Cebula, E., Persky, D., Lossos, I., Agarwal, A. B., Jung, J., Burack, R., Zhou, X., Leonard, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8793 · Cited by 212
Morschhauser, F. A., Cartron, G., Thieblemont, C., Solal-Céligny, P., Haioun, C., Bouabdallah, R., Feugier, P., Bouabdallah, K., Asikanius, E., Lei, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9585 · Cited by 206
Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203
Ott, G., Ziepert, M., Klapper, W., Horn, H., Szczepanowski, M., Bernd, H.-W., Thorns, C., Feller, A. C., Lenze, D., Hummel, M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276766 · Cited by 202
Dubois, S., Viailly, P.-J., Mareschal, S., Bohers, E., Bertrand, P., Ruminy, P., Maingonnat, C., Jais, J.-P., Peyrouze, P., Figeac, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2305 · Cited by 200
Self-citationYounes, A., Berdeja, J. G., Patel, M. R., Flinn, I., Gerecitano, J. F., Neelapu, S. S., Kelly, K. R., Copeland, A. R., Akins, A., Clancy, M. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00584-7 · Cited by 186
Howlett, C., Snedecor, S. J., Landsburg, D. J., Svoboda, J., Chong, E. A., Schuster, S. J., Nasta, S. D., Feldman, T., Rago, A., Walsh, K. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13463 · Cited by 177
Iqbal, J., Meyer, P. N., Smith, L. M., Johnson, N. A., Vose, J. M., Greiner, T. C., Connors, J. M., Staudt, L. M., Rimsza, L., Jaffe, E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0267 · Cited by 176
Vose, J. M., Carter, S., Burns, L. J., Ayala, E., Press, O. W., Moskowitz, C. H., Stadtmauer, E. A., Mineshi, S., Ambinder, R., Fenske, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9453 · Cited by 173
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 169
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas
Sarkozy, C., Traverse-Glehen, A., & Coiffier, B. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00005-4 · Cited by 168
Self-citationFayad, L., Offner, F., Smith, M. R., Verhoef, G., Johnson, P., Kaufman, J. L., Rohatiner, A., Advani, A., Foran, J., Hess, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7211 · Cited by 160
Self-citationJardin, F., Jaïs, J., Molina, T. J., Parmentier, F., Picquenot, J., Ruminy, P., Tilly, H., Bastard, C., Salles, G. A., Feugier, P., et al. (2010) · Blood · doi:10.1182/blood-2009-10-247122 · Cited by 159
Self-citationPfeifer, M., Zheng, B., Erdmann, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.48 · Cited by 152
Targeting BCL2 for the Treatment of Lymphoid Malignancies
Anderson, M. A., Huang, D. C. S., & Roberts, A. W. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.008 · Cited by 151
Bittenbring, J. T., Neumann, F., Altmann, B., Achenbach, M., Reichrath, J., Ziepert, M., Geisel, J., Regitz, E., Held, G., & Pfreundschuh, M. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.4537 · Cited by 137
Camus, V., Lanic, H., Kraut, J., Modzelewski, R., Clatot, F., Picquenot, J. M., Contentin, N., Lenain, P., Groza, L., Lemasle, É., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12285 · Cited by 133
Epigenomic evolution in diffuse large B-cell lymphomas
Pan, H., Jiang, Y., Boi, M., Tabbò, F., Redmond, D., Nie, K., Ladetto, M., Chiappella, A., Cerchietti, L. C. A., Shaknovich, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms7921 · Cited by 132
Nam, S. J., Go, H., Paik, J. H., Kim, T., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.879713 · Cited by 126
Huang, X., Meng, B., Iqbal, J., Ding, B. B., Perry, A. M., Cao, W., Smith, L. M., Bi, C., Jiang, C., Greiner, T. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6004 · Cited by 126
Crump, M., Leppä, S., Fayad, L., Lee, J. J., Rocco, A. D., Ogura, M., Hagberg, H., Schnell, F. M., Rifkin, R. M., Mackensen, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7171 · Cited by 125
Porrata, L. F., Ristow, K., Habermann, T., Inwards, D. J., Micallef, I. N., & Markovic, S. N. (2010) · American Journal of Hematology · doi:10.1002/ajh.21849 · Cited by 124
Lu, T., Liang, J., Miao, Y., Fan, L., Wang, L., Qu, X., Cao, L., Gong, Q., Wang, Z., Zhang, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep12168 · Cited by 115
Shimoni, A., Avivi, I. M., Rowe, J. M., et al. (2012) · Cancer · doi:10.1002/cncr.27418 · Cited by 107
Vacirca, J. L., Acs, P. I., Tabbara, I. A., Rosen, P. J., Lee, P., & Lynam, E. B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1879-x · Cited by 106
de Vos, S., Forero, A., Ansell, S. M., Kahl, B. S., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H. G., Timmerman, J. M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-44 · Cited by 105
Keane, C., Gill, D. S., Vari, F., Cross, D., Griffiths, L. R., & Gandhi, M. K. (2013) · American Journal of Hematology · doi:10.1002/ajh.23398 · Cited by 104
Bairey, O., Shacham‐Abulafia, A., Shpilberg, O., & Gurion, R. (2015) · Hematological Oncology · doi:10.1002/hon.2233 · Cited by 103
Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma
Nakamura, N., Hara, T., Shibata, Y., Matsumoto, T., Nakamura, H., Ninomiya, S., Kito, Y., Kitagawa, J., Kanemura, N., Goto, N., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2499-4 · Cited by 103
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
Yang, Y., Kelly, P. N., Shaffer, A. L., Schmitz, R., Yoo, H. M., Liu, X., Huang, D. W., Webster, D. E., Young, R. M., Nakagawa, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.006 · Cited by 102
Jiang, Y., Redmond, D., Nie, K., Eng, K. W., Clozel, T., Martin, P., Tan, L. H. C., Melnick, A. M., Tam, W., & Elemento, O. (2014) · Genome biology · doi:10.1186/s13059-014-0432-0 · Cited by 99
Jaeger, U., Trněný, M., Melzer, H., Praxmarer, M., Nawarawong, W., Yehuda, D. B., Goldstein, D. S., Mihaljević, B., İlhan, O., Ballová, V., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125344 · Cited by 86
Li, C., Thompson, M. A., Tamayo, A. T., Zuo, Z., Lee, J., Vega, F., Ford, R. J., & Pham, L. V. (2012) · Oncotarget · doi:10.18632/oncotarget.463 · Cited by 85
Wieringa, A., Boslooper, K., Hoogendoorn, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12765 · Cited by 81
Chen, J., Xu-Monette, Z. Y., Deng, L., Shen, Q., Manyam, G. C., Martínez-López, A., Zhang, L., Montes‐Moreno, S., Visco, C., Tzankov, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3343 · Cited by 77
Johnson-Farley, N. N., Veliz, J., Bhagavathi, S., & Bertino, J. R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.981172 · Cited by 74
Flinn, I. W., Bartlett, N. L., Blum, K. A., Ardeshna, K. M., LaCasce, A. S., Flowers, C. R., Shustov, A. R., Thress, K. S., Mitchell, P., Zheng, F., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.005 · Cited by 74
Nols, N., Mounier, N., Bouazza, S., Lhommel, R., Costantini, S., Borght, T. V., Vekemans, M., Sonet, A., Bosly, A., Michaux, L., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.831848 · Cited by 73
Adams, H. J. A., Nievelstein, R. A. J., & Kwee, T. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13420 · Cited by 72
Novak, A. J., Asmann, Y. W., Maurer, M. J., Wang, C., Slager, S. L., Hodge, L. S., Manske, M. K., Price-Troska, T. L., Yang, Z.-Z., Zimmermann, M. T., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.69 · Cited by 68
The Epigenetic Basis of Diffuse Large B-Cell Lymphoma
Jiang, Y., & Melnick, A. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.003 · Cited by 68
High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma
Marques, S. C., Ranjbar, B., Laursen, M. B., Falgreen, S., Bilgrau, A. E., Bødker, J. S., Jørgensen, L. K., Primo, M. N., Schmitz, A., Ettrup, M. S., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2015.12.007 · Cited by 67
Mozos, A., Roué, G., López‐Guillermo, A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.07.031 · Cited by 66
Matasar, M. J., Czuczman, M. S., Rodriguez, M. A., Fennessy, M., Shea, T. C., Spitzer, G., Lossos, I. S., Kharfan‐Dabaja, M. A., Joyce, R., Fayad, L., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472027 · Cited by 66
Troppan, K. T., Schlick, K., Deutsch, A. J. A., Melchardt, T., Egle, A., Stojaković, T., Beham‐Schmid, C., Weiss, L., Neureiter, D., Wenzl, K., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.277 · Cited by 66
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Xu-Monette, Z. Y., Deng, Q., Manyam, G. C., Tzankov, A., Li, L., Xia, Y., Wang, X., Zou, D., Visco, C., Dybkær, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2296 · Cited by 66
Song, M.-K., Yang, D., Lee, G., Lim, S.-N., Shin, S., Pak, K. J., Kwon, S. Y., Shim, H., Choi, B.-H., Kim, I., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.01.010 · Cited by 60
Lemma, S. A., Karihtala, P., Haapasaari, K., Jantunen, E., Soini, Y., Bloigu, R., Pasanen, A. K., Turpeenniemi-Hujanen, T. M., & Kuittinen, O. M. (2012) · Histopathology · doi:10.1111/his.12000 · Cited by 59
TP53 dysfunction in diffuse large B-cell lymphoma
Lu, T., Young, K. H., Xu, W., & Li, J.-Y. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.006 · Cited by 58
Li, Y., Pan, Y.-Y., Jiao, Y., Ning, J., Fan, Y., & Zhai, Z. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1916-9 · Cited by 58
Song, G., Gu, L., Li, J., Tang, Z., Liu, H., Chen, B., Sun, X., He, B., Pan, Y., Wang, S., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2111-3 · Cited by 57
Ma, J., Xing, W., Coffey, G., Dresser, K., Lu, K., Guo, A., Raca, G., Pandey, A., Conley, P. B., Yu, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6316 · Cited by 56
Scandurra, M., Mian, M., Greiner, T. C., Rancoita, P. M. V., de Campos, C. P., Chan, W. C., Vose, J. M., Chigrinova, E. R., Inghirami, G., Chiappella, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08326.x · Cited by 54
Feldman, T. A., Mato, A. R., Chow, K. F., Protomastro, E., Yannotti, K., Bhattacharyya, P. K., Yang, X. Y., Donato, M. L., Rowley, S. D., Carini, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12846 · Cited by 52
Peng, W., Wu, J., & Feng, J. (2015) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0396-8 · Cited by 52
Bedekovics, T., Hussain, S., Feldman, A. L., & Galardy, P. J. (2015) · Blood · doi:10.1182/blood-2015-07-656678 · Cited by 49
Gratzinger, D. A., Advani, R. H., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S. J., Sehn, L. H., Farinha, P., Briones, J., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07942.x · Cited by 48
Ansell, S. M., Maurer, M. J., Ziesmer, S. C., Slager, S. L., Habermann, T. M., Link, B. K., Witzig, T. E., Macon, W. R., Doǧan, A., Cerhan, J. R., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23259 · Cited by 44
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma
Šmardová, J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1170 · Cited by 43
Forero, A., Bartlett, N. L., Beaven, A., Myint, H., Nasta, S. D., Northfelt, D., Whiting, N. C., Drachman, J. G., LoBuglio, A. F., & Moskowitz, C. H. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.710328 · Cited by 43
Puvvada, S. D., Li, H., Rimsza, L. M., Bernstein, S. H., Fisher, R. I., LeBlanc, M. L., Schmelz, M., Glinsmann‐Gibson, B., Miller, T. P., Maddox, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1135431 · Cited by 41
Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
Phipps‐Yonas, H., Cui, H., Sebastiao, N., Brunhoeber, P., Haddock, E. S., Deymier, M. J., Klapper, W., Lybarger, L. P., Roe, D. J., & Hastings, K. T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00425 · Cited by 39
Kaneko, N., Mitsuoka, K., Amino, N., Yamanaka, K., Kita, A., Mori, M., Miyoshi, S., & Kuromitsu, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2707 · Cited by 38
Barr, P. M., Miller, T. P., Friedberg, J. W., Peterson, D. R., Baran, A. M., Herr, M. M., Spier, C. M., Cui, H., Roe, D. J., Persky, D. O., et al. (2014) · Blood · doi:10.1182/blood-2014-04-570044 · Cited by 37
Kristensen, L. S., Asmar, F., Dimopoulos, K., Nygaard, M. K., Aslan, D., Hansen, J. W., Ralfkiaer, E. M., & Grønbæk, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2394 · Cited by 35
Tzankov, A., Leu, N., Muenst, S. E., Juškevičius, D., Klingbiel, D., Mamot, C., & Dirnhofer, S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0168-7 · Cited by 34
Arcari, A., Chiappella, A., Spina, M., Zanlari, L., Bernuzzi, P., Valenti, V., Tani, M., Marasca, R., Cabras, M. G., Zambello, R., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1106536 · Cited by 34
Straus, D. J., Hamlin, P. A., Matasar, M. J., Palomba, M. L., Drullinsky, P. R., Zelenetz, A. D., Gerecitano, J. F., Noy, A., Hamilton, A. M., Elstrom, R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13195 · Cited by 33
Chan, F. C., Telenius, A., Healy, S., Ben‐Neriah, S., Mottok, A., Lim, R. S., Drake, M., Hu, S., Ding, J., Ha, G., et al. (2014) · Blood · doi:10.1182/blood-2013-06-507152 · Cited by 28
Martı́n, A., Redondo, A., Dlouhy, I., Salar, A., González-Barca, E. M., Canales, M. Á., Montes‐Moreno, S., Ocio, E. M., López‐Guillermo, A., Caballero, D. M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13945 · Cited by 28
Mitsuhashi, K., Masuda, A., Wang, Y., Shiseki, M., & Motoji, T. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1593-z · Cited by 27
Asmar, F., Hother, C. E., Kulosman, G., Treppendahl, M. B., Nielsen, H. M., Ralfkiær, U., Pedersen, A., Møller, M. B., Ralfkiaer, E. M., Brown, P. D. N., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1877 · Cited by 26
Okina, S., Yanagisawa, N., Yokoyama, M., Sakurai, Y., Numata, Y., Umezawa, A., Higashihara, M., & Murakumo, Y. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1880-3 · Cited by 25
Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma
Adams, H. J. A., de Klerk, J. M. H., Fijnheer, R., Heggelman, B. G. F., Dubois, S. V., Nievelstein, R. A. J., & Kwee, T. C. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.639 · Cited by 25
Lee, H. J., Shin, D. H., Kim, K. B., Shin, N., Park, W. Y., Lee, J. H., Choi, K. U., Kim, J. Y., Lee, C. H., & Sol, M. Y. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.858816 · Cited by 24
Paik, J. H., Nam, S. J., Kim, T. M., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-911 · Cited by 23
Eyre, T. A., Linton, K., Rohman, P., Kothari, J., Cwynarski, K., Ardeshna, K. M., Bailey, C., Osborne, W., Rowntree, C. J., Eden, D. T., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14021 · Cited by 22
Ok, C. Y., Xu-Monette, Z. Y., Li, L., Manyam, G. C., Montes‐Moreno, S., Tzankov, A., Visco, C., Dybkær, K., Routbort, M. J., Zhang, L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.76 · Cited by 21
Song, G., Cho, W. C. S., Gu, L., He, B., Pan, Y., & Wang, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0056-y · Cited by 21
Beheshti, A., Neuberg, D. S., McDonald, J. T., Vanderburg, C. R., & Evens, A. M. (2015) · Cancer Informatics · doi:10.4137/cin.s34144 · Cited by 21
Fang, C., Zhu, D., Dong, H., Ji, M., Wu, J., Xu, X., Cheng, G., Wu, C., & Jiang, J. (2015) · PubMed Central · Cited by 21
Wang, Y., Li, Y.-J., Jiang, W.-Q., Rao, H., Huang, J.-J., Xia, Y., Bi, X., Sun, P., Huang, H.-Q., Lin, T.-Y., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2490-0 · Cited by 16
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
Cheson, B. D., & Crawford, J. (2015) · British Journal of Haematology · doi:10.1111/bjh.13321 · Cited by 12
Barton, S. R., Hawkes, E. A., Cunningham, D., Peckitt, C., Chua, S., Wotherspoon, A. C., Attygalle, A. D., Horwich, A., Potter, M. N., Ethell, M. E., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12416 · Cited by 12
Nobili, S., Napoli, C., Puccini, B., Landini, I., Perrone, G., Brugia, M., Benelli, G., Doria, M., Martelli, M., Finolezzi, E., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.866665 · Cited by 7
Ishii, Y., Tomita, N., Tateishi, U., Ishiyama, Y., Yamamoto, E. M., Hattori, Y., Hagihara, M., Yamazaki, E., & Ishigatsubo, Y. (2014) · Medical Oncology · doi:10.1007/s12032-014-0880-0 · Cited by 5
Hu, Y., Ding, N., Jin, X. S., Feng, L., Ping, L., Song, Y., & Zhu, J. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-25 · Cited by 5
Research works printed but not linked: 47
- Xu-Monette, 2015, Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP, Mod Pathol, 28, 1555, 10.1038/modpathol.2015.118 · doi:10.1038/modpathol.2015.118
- Caponetti, 2015, Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome, Leuk Lymphoma, 56, 3082, 10.3109/10428194.2015.1034699 · doi:10.3109/10428194.2015.1034699
- Savage, 2016, Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL, Blood, 127, 2182, 10.1182/blood-2015-10-676700 · doi:10.1182/blood-2015-10-676700
- Cuccuini, 2012, MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation, Blood, 119, 4619, 10.1182/blood-2012-01-406033 · doi:10.1182/blood-2012-01-406033
- Oki, 2014, Double hit lymphoma: the MD Anderson Cancer Center clinical experience, Br J Haematol, 166, 891, 10.1111/bjh.12982 · doi:10.1111/bjh.12982
- Puvvada, 2016, Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704, Br J Haematol, 174, 686, 10.1111/bjh.14100 · doi:10.1111/bjh.14100
- Mounier, 2012, Relapses, treatments and new drugs, Best Pract Res Clin Haematol, 25, 49, 10.1016/j.beha.2012.01.002 · doi:10.1016/j.beha.2012.01.002
- Sauter, 2015, Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma, Blood, 125, 2579, 10.1182/blood-2014-10-606939 · doi:10.1182/blood-2014-10-606939
- Witzig, 2016, PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL) [abstract], J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.7506 · doi:10.1200/jco.2016.34.15_suppl.7506
- Friedberg, 2014, R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433, Br J Haematol, 166, 382, 10.1111/bjh.12906 · doi:10.1111/bjh.12906
- Witzig, 2015, A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402, Br J Haematol, 170, 679, 10.1111/bjh.13493 · doi:10.1111/bjh.13493
- Bielska, 2015, Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma, Genes Chromosomes Cancer, 54, 185, 10.1002/gcc.22235 · doi:10.1002/gcc.22235
- Hasselblom, 2010, High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Br J Haematol, 149, 560, 10.1111/j.1365-2141.2010.08123.x · doi:10.1111/j.1365-2141.2010.08123.x
- Alinari, 2016, De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort, Am J Hematol, 91, 395, 10.1002/ajh.24299 · doi:10.1002/ajh.24299
- Adams, 2015, Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma, Eur J Radiol, 84, 372, 10.1016/j.ejrad.2014.12.009 · doi:10.1016/j.ejrad.2014.12.009
- Gaudio, 2011, High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab, Acta Haematol, 126, 44, 10.1159/000324206 · doi:10.1159/000324206
- Goto, 2012, Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens, Ann Hematol, 91, 705, 10.1007/s00277-011-1363-4 · doi:10.1007/s00277-011-1363-4
- Yamauchi, 2012, Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma, Anticancer Res, 32, 5051
- Yuan, 2016, Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients, Oncol Lett, 11, 423, 10.3892/ol.2015.3866 · doi:10.3892/ol.2015.3866
- Arima, 2013, Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 2645, 10.3109/10428194.2013.788697 · doi:10.3109/10428194.2013.788697
- Goto, 2012, Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, Leuk Lymphoma, 53, 1494, 10.3109/10428194.2012.660627 · doi:10.3109/10428194.2012.660627
- Goto, 2011, Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens, Eur J Haematol, 87, 217, 10.1111/j.1600-0609.2011.01649.x · doi:10.1111/j.1600-0609.2011.01649.x
- Xu-Monette, 2016, Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma, Clin Cancer Res, 22, 3593, 10.1158/1078-0432.CCR-15-2296 · DOI
- Hao, 2015, The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma, PLoS One, 10, e0126615, 10.1371/journal.pone.0126615 · doi:10.1371/journal.pone.0126615
- Higashi, 2016, Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma, Leuk Lymphoma, 57, 161, 10.3109/10428194.2015.1038708 · DOI
- Hedström, 2013, Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL), Int J Hematol, 97, 465, 10.1007/s12185-013-1303-2 · doi:10.1007/s12185-013-1303-2
- Jardin, 2013, Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 1898, 10.3109/10428194.2013.767456 · doi:10.3109/10428194.2013.767456
- Jin, 2012, Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP, J Hematol Oncol, 5, 51, 10.1186/1756-8722-5-51 · doi:10.1186/1756-8722-5-51
- Koh, 2013, Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP, Cancer Sci, 104, 1245, 10.1111/cas.12215 · DOI
- Jung, 2012, Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study, Ann Hematol, 91, 1747, 10.1007/s00277-012-1516-0 · doi:10.1007/s00277-012-1516-0
- Markovic, 2012, Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL), Med Oncol, 29, 3515, 10.1007/s12032-012-0232-x · doi:10.1007/s12032-012-0232-x
- Choi, 2016, High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy, Int J Hematol, 103, 210, 10.1007/s12185-015-1911-0 · doi:10.1007/s12185-015-1911-0
- Miyashita, Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy [published online ahead of print 29 August, 2015], Leuk Res
- Nakamura, 2013, Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen, Eur J Haematol, 91, 322, 10.1111/ejh.12139 · doi:10.1111/ejh.12139
- Rossi, 2011, The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma, Blood, 117, 2405, 10.1182/blood-2010-07-296244 · doi:10.1182/blood-2010-07-296244
- Ni, 2015, Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP, Biomarkers, 20, 253, 10.3109/1354750X.2015.1068855 · doi:10.3109/1354750x.2015.1068855
- Wong, 2015, Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP, Exp Mol Pathol, 99, 537, 10.1016/j.yexmp.2015.08.019 · doi:10.1016/j.yexmp.2015.08.019
- Yıldırım, 2015, The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis, Arch Med Sci, 11, 708, 10.5114/aoms.2015.53289 · doi:10.5114/aoms.2015.53289
- Choi, 2016, Prognostic implication of semi-quantitative immunohistochemical assessment of CD20 expression in diffuse large B-cell lymphoma, J Pathol Transl Med, 50, 96, 10.4132/jptm.2016.01.12 · doi:10.4132/jptm.2016.01.12
- Ageberg, 2013, The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death, Am J Transl Res, 5, 170
- Brander, 2013, Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 2627, 10.3109/10428194.2013.784969 · doi:10.3109/10428194.2013.784969
- Buckstein, 2011, Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group, Leuk Lymphoma, 52, 833, 10.3109/10428194.2011.555892 · doi:10.3109/10428194.2011.555892
- Coiffier, 2016, A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, Br J Haematol, 173, 722, 10.1111/bjh.13992 · doi:10.1111/bjh.13992
- Evens, 2013, A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas, Br J Haematol, 163, 55, 10.1111/bjh.12488 · doi:10.1111/bjh.12488
- Fayad, 2015, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial, Leuk Lymphoma, 56, 2569, 10.3109/10428194.2015.1007504 · doi:10.3109/10428194.2015.1007504
- Mahadevan, 2014, Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2, PLoS One, 9, e95184, 10.1371/journal.pone.0095184 · doi:10.1371/journal.pone.0095184
- Matsumoto, A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy [published online ahead of print 21 March 2016], Hematol Oncol
Cited by
Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., Gaidano, G., André, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30225-4 · Cited by 533
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C. W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., & Xu, S. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3588 · Cited by 7
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2504719 · Cited by 5
Metadata
- Authors
- Coiffier, B., & Sarkozy, C.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2016-12-02
- Volume
- 2016
- Issue
- 1
- Pages
- 366-378
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2559431510
- Cited by
- 292
- References
- 112
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.